Os(ii) complexes for catalytic anticancer therapy: recent update

Abstract

The recent dramatic enhancement in the cancer-related mortality and drawbacks (side effects and resistance) of Pt-based first-generation chemotherapeutics have escalated the need for new cancer medicines with unique anticancer activities...

Metal Complexes for Cancer Sonodynamic Therapy

“…The development of photodynamic therapy (PDT) offered a harmless non‐invasive cancer treatment in which light exposure activates a non‐toxic photosensitizer at the target tumor site [14,15] . In the presence of molecular oxygen, the activated photosensitizer produces 1 O 2 and/or other reactive oxygen species (ROS), which causes cell death [14,16] . Interestingly, PDT has offered great results only for superficial cancers due to the low penetration of light into deeper tissues [17] .…”

“…[14,15] In the presence of molecular oxygen, the activated photosensitizer produces 1 O 2 and/or other reactive oxygen species (ROS), which causes cell death. [14,16] Interestingly, PDT has offered great results only for superficial cancers due to the low penetration of light into deeper tissues. [17] To overcome the light penetration problem in cancer PDT, sonodynamic therapy (SDT) has emerged as another noninvasive cancer therapy.…”

Polypyridyl CoII‐Curcumin Complexes as Photoactivated Anticancer and Antibacterial Agents

“…[4][5][6][7] Recently, photodynamic therapy (PDT) with metal-based photosensitizers has evolved for nextgeneration cancer treatment. [7][8][9][10][11][12][13][14][15] This strategy can offer fewer side effects and resistance. [16,17] Therefore, the development of new metal-based photosensitizers for photodynamic therapy has gained great interest.…”

Cyclometalated Benzimidazole Osmium(II) Complexes with Antiproliferative Activity in Cancer Cells Disrupt Calcium Homeostasis

“…The well-known toxicity of OsO 4 was partially the cause of the rejection of the use of osmium complexes as anticancer agents . However, given the clinical success of ruthenium complexes, which entered and progressed into clinical trials, research efforts have been directed toward investigating the therapeutic properties of osmium complexes. , First, osmium-based compounds were synthesized as analogues of prototypal ruthenium­(III) complexes (NAMI-A, RAPTA-C, and RM-175), showing better properties when changing the metal. − Subsequently, the anticancer activity of half-sandwich complexes was explored. Sadler and co-workers developed osmium­(II) complexes containing azopyridine ligands, which were active against various cancer cell lines .…”

“… 5 However, given the clinical success of ruthenium complexes, which entered and progressed into clinical trials, research efforts have been directed toward investigating the therapeutic properties of osmium complexes. 6 , 7 First, osmium-based compounds were synthesized as analogues of prototypal ruthenium(III) complexes (NAMI-A, RAPTA-C, and RM-175), showing better properties when changing the metal. 8 − 10 Subsequently, the anticancer activity of half-sandwich complexes was explored.…”